Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

100%

3 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 4
2(66.7%)
Phase 3
1(33.3%)
3Total
Phase 4(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02339064Phase 3Active Not Recruiting

Infusion of Apomorphine: Long-term Safety Study

Role: lead

NCT02549573Phase 4Terminated

Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®

Role: lead

NCT01770145Phase 4Completed

Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)

Role: lead

All 3 trials loaded